Clinical Analysis of Elderly Patients with AML/High-Risk MDS.
10.19746/j.cnki.issn.1009-2137.2022.05.002
- Author:
Wen-Yan XU
1
;
Fang WANG
1
;
Li LIU
1
;
Xiu-Hong REN
1
;
Ping-Ping LIU
1
;
Hao ZHANG
1
;
Li ZHENG
1
;
Song-Song ZHANG
1
;
Ya-Ru XU
1
;
Zhen-Xing GUO
2
Author Information
1. Department of Hematology & Oncology, The First Affiliated Hospital of Tsinghua University, Beijing 100016, China.
2. Department of Hematology & Oncology, The First Affiliated Hospital of Tsinghua University, Beijing 100016, China.E-mail: gzx2962@outlook.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
chemotherapy;
elderly patient;
myelodysplastic syndrome;
supportive treatmen
- MeSH:
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Middle Aged;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(5):1311-1317
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical features of acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS) patients aged over 60 years old.
METHODS:The clinical data of 61 elderly newly diagnosed patients with AML and high-risk MDS who submitted to the Department of Hematology/Oncology of the First Affiliated Hospital of Tsinghua University from January 2009 to April 16, 2021 were retrospectively analyzed. These patients were divided into chemotherapy group (45 cases) and supportive treatment group (16 cases). The overall survival (OS) was analyzed by Kaplan-Meier method, and the prognostic factors of survival were analyzed by multivariate Cox regression.
RESULTS:After 2 cycles of induction chemotherapy, the complete remission (CR) rate was 37.8% (17/45), and overall response rate was 62.2% (28/45) in the chemotherapy group. The median OS in the chemotherapy group and supportive treatment group was 11.3 (0.07-43) and 1.6 (0.33-7.72) months, respectively (P<0.001). The median OS in patients who reached CR or did not reach after 1 cycle of induction chemotherapy was 19.8 (10-30.63) and 8.17 (0.07-43) months, respectively (P<0.05), while after 2 cycles was 22.7 (4.2-43) and 7.26 (0.07-26) months, respectively (P<0.001). Univariate analysis showed that age > 80 years old, CCI score > 2, PS score > 2 and supportive treatment were the adverse prognostic factors for OS. Further multivariate analysis suggested that chemotherapy was the only independent prognostic factor for OS (HR=0.140, 95%CI: 0.048-0.409, P<0.001). In the chemotherapy group, univariate analysis showed that CCI score > 2 and failure to reach CR after induction chemotherapy were poor prognostic factors. Multivariate analysis showed that CCI score > 2 (HR=0.139, 95%CI: 0.050-0.384, P<0.001) and failure to achieve CR after induction chemotherapy (HR=0.103, 95%CI: 0.041-0.259, P<0.001) were the adverse prognostic factors for OS. The patients were tolerant to side-effect of chemotherapy.
CONCLUSION:Appropriate chemotherapy can prolong the survival of elderly patients with AML and high-risk MDS.
